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Abstract To assess the need for adjustment in the likeli-
hood of germline BRCA1/2 mutations in women with
HER2? breast cancers. We analysed primary mutation
screens on women with breast cancer with unequivocal
HER2 overexpression and assessed the likelihood of
BRCA1/BRCA2 mutations by age, oestrogen receptor status
and Manchester score. Of 1111 primary BRCA screens
with confirmed HER2 status only 4/161 (2.5%) of women
with HER2 amplification had a BRCA1 mutation identified
and 5/161 (3.1%) a BRCA2 mutation. The pathology
adjusted Manchester score between 10 and 19% and 20%?
thresholds resulted in a detection rate of only 6.5 and 15%
respectively. BOADICEA examples appeared to make
even less downward adjustment. There is a very low
detection rate of BRCA1 and BRCA2 mutations in women
with HER2 amplified breast cancers. The Manchester score
and BOADICEA do not make sufficient downward
adjustment for HER2 amplification. For unaffected women,
assessment of breast cancer risk and BRCA1/2 probability
should take into account the pathology of the most relevant
close relative. Unaffected women undergoing mutation
testing for BRCA1/2 should be advised that there is limited
reassurance from a negative test result if their close relative
had a HER2? breast cancer.
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Introduction
Although the pathology of breast cancers associated with
BRCA1 and to a lesser extent BRCA2 is well documented
[1–3], the likelihood of identifying a BRCA1 or BRCA2
mutation in HER2 amplified breast cancer is not well
described. Most risk algorithms for assessing the likelihood
of a BRCA1/2 mutation were developed before the ability
to adjust for pathology, particularly relevant for BRCA1
where the majority of breast cancers are high grade and
triple negative (estrogen receptor (ER), progesterone
receptor (PR) and HER2 negative) [4–8]. The speed and
reduced expense of modern BRCA mutation screening may
lead to a perceived reduction in the importance of mutation
likelihood assessment. However, difficulties in interpreta-
tion of mutation testing arise when a variant of uncertain
significance (VUS) is found. Furthermore many countries
still utilise likelihood thresholds for a sample to be tested,
which in the UK remains at 10% [9]. Until there are
licensed medications, approved by healthcare systems, for
precision medicine approaches for breast cancer related to
BRCA1/2 such as PARPi, these thresholds are likely to
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remain. Knowing the a priori likelihood of an individual
having a pathogenic mutation is helpful in interpreting
VUS reports [3] that affect around 5% of tested individuals.
More importantly, for those individuals testing negative for
a BRCA1/2 mutation screen who do not have cancer, and
are from a family without testing of an affected member, it
is not possible to assess the degree of reassurance of a
negative test without knowledge of the likelihood that their
affected relative was a BRCA1 or BRCA2 mutation carrier.
Attempts have been made to incorporate breast pathology
into risk algorithms such as the Manchester scoring system
[10] and BOADICEA [11, 12] and these improve the
accuracy of likelihood estimates and risk thresholds
[10, 13]. Periodic revisions of these scoring systems are
useful, as most ‘classical’ high penetrance BRCA mutation
carrier families will have been identified, leaving less
classical phenotypes to be uncovered. Therefore incorpo-
rating additional data, such as receptor status, is worth-
while to develop and update the chance algorithms. Partly
because of its relatively recent introduction, data on HER2
remains relatively scarce. We have therefore interrogated
our data on BRCA1/2 primary mutation screens in women
with invasive breast cancer and our BRCA1 and BRCA2
family register service databases to address the question of
breast pathology in primary screens and of the proportion
of BRCA1 and BRCA2 breast cancers that are triple nega-
tive or HER2 amplified [14]. We also subdivided HER2
amplified cancers by ER expression.
Methods
Women with breast cancer have been tested for BRCA1/2
mutations in Manchester since 1996. Data on women with
breast cancer who had undergone BRCA1/2 testing were
obtained from those undergoing primary full screens for
BRCA1/2 mutations with sequencing of all exons and
Multiple Ligation dependent Probe Amplification (MLPA)
to assess for whole or multiple exon deletions or duplica-
tions as previously described [10]. Only women with
confirmed pathogenic mutations were included as BRCA1
or BRCA2 positive. Whilst risk thresholds for testing were
quite stringent with a 20% threshold for testing until 2013,
the majority of women with at least a 10% probability for a
BRCA1/2 mutation and several at less than this had access
to testing through research protocols.
All primary breast cancers occurring after 1990 (in-
cluding contralateral) when hormone receptor testing star-
ted to be carried out routinely were included. HER2 testing
did not become routine in the UK until around 2005. Data
were collected prospectively on all women with breast
cancer tested for BRCA1/2 from 2005 and retrospectively
for cases tested before that date. The study represents a
semi-prospective consecutive series of women with breast
cancer where HER2 status was assessable.
Confirmation of HER2 positivity
HER2 status was assessed from local pathology reports and
defined as positive if (1)– scored 3? by immunohisto-
chemistry or (2) amplified by Fluorescent (or other) In Situ
Hybridisation (ISH) with a HER2:CEP17 ratio of[2.0 or
HER2 amplicon[6 if no CEP17 probe was employed. All
negative, unconfirmed and borderline cases were excluded
including those where tumours scored IHC 2? from the
pathology report and no supplementary FISH report was
available.
Confirmation of ER negativity
Breast cancers were classified as ER-ve based on pathology
reports from clinical records and cancer registry data. ER
was assessed as either a percentage staining (0–100%) or as
a quickscore (QS) (0–8). A tumor was considered ER
positive with a QS of 6–8 and or staining of[10%. ER
negativity was confirmed if QS was \4 and or ER was
\10%. Tumors with intermediate scores were excluded.
Confirmation of triple negativity
From 2005, PR was also routinely tested and classification
was identical to that of ER. PR positivity was not recorded
on the mutation database but if ER and HER2 were neg-
ative and PR had a QS of\4 and or percentage was\10%,
tumors were considered triple negative for the database.
Manchester scores were derived by summating scores
for BRCA1 and BRCA2 for each breast, ovarian or prostate
cancer primary in the same lineage. An adjustment of -4
points was made for a HER2? breast cancer and ?4 for a
grade 3 triple negative breast cancer as previously descri-
bed [10]. Two sided Chi-square tests with Fisher’s exact
correction were used to compare proportions.
Ethics approval for the study was through the North
Manchester Research (08/H1006/77) and University of
Manchester ethics committees (08229).
Results
There were 1134 women with breast cancer with verified
HER2 and ER status who had undergone full mutation
screening of BRCA1 and BRCA2 (Table 1). Included were
619 of the total of 803 (77%) samples that had BRCA
tested in Manchester in the last 4 years (since 01/11/2011).
Twenty-three women with breast cancer were excluded
from the main analysis as their tumours were ER negative
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and PR positive, resulting in 1111 eligible women with ER/
PR negative tumour with a known HER2 status. The
majority (n = 101) of the 184 women in the most recent
era (2010–2015) without HER2 status were diagnosed with
breast cancer before 2005, 78 (9.8%) had no available
pathology report and the remaining five (0.6%) were HER2
2? without available FISH testing from clinical notes. Of
the 1111 women, 161 (14.5%) had HER2 amplified breast
cancer. 114/161 (71%) were ER positive. Only 9/161
(5.6%) of BRCA tests in HER2? women identified a
pathogenic mutation. Five of 114 (4.4%) of ER? HER2?
cancers had mutations (4 BRCA2) and 4/45 (9%) of ER-
HER2? (3 BRCA1). In contrast, of 425 screens in women
with triple negative breast cancer, 151 (35.5%) resulted in
positive BRCA tests with 117 (27.5%) having BRCA1
mutations and 34 (8.0%) BRCA2 mutations. Even with a
combined pathology adjusted Manchester score [10] of 20
or higher indicating at least a 20% likelihood of a BRCA1/2
mutation only 5/33 (15%) women with HER2? breast
cancer had a mutation identified. However, this was 4/10
(40%) of ER- HER? cancers and only 1/23 (4.4%; 95%
CI 0–12.7%) of ER? HER2- cancers (p = 0.02). It was
not really possible to assess the 10% threshold with a
Manchester score of 15–19 as only seven breast cancers
that were ER- HER2? were tested one of which (14%)
had a BRCA2 mutation. None of 22 sporadic HER2?
breast cancers had a BRCA1/2 mutation, but 2/13 (15%)
diagnosed \35 years had a TP53 mutation. In contrast
120/215 (55.8%) of those with triple negative breast cancer
and a Manchester score above 20 had a mutation identified,
rising to 83% in women with a Manchester score of 30 or
higher.
Interestingly, the 10% threshold was not met with triple
negative breast cancers with a Manchester score of\14 (6/
85 = 7.0%), nor with sporadic triple negative cases of
breast cancer aged\50 years at diagnosis (8/94 = 8.5%).
Discussion
This present study has demonstrated a very low frequency
of detection of BRCA1 and BRCA2 mutation carriers
amongst primary screens of women with HER2 amplified
breast cancers, particularly those with ER? ve tumours.
Overall, these low rates do not appear to be fully accounted
for in the pathology adjusted Manchester scoring system
with the 10% risk combined threshold not being met in
women with scores of 14–19 and the 20% threshold not
being met in women with Manchester scores of 20 or
higher (5/33–15%), excepting those that were ER-ve. In
practice, this suggests that women with ER? HER2 posi-
tive breast cancers should be advised that they are unlikely
to harbour a BRCA1/2 mutation unless there are other very
suggestive features in their own personal or family histo-
ries (other more typical breast cancer or ovarian cancer).
Additionally, women who are offered testing whose mother
or sister had a HER2 positive breast cancer will get little
reassurance regarding breast cancer risk from a negative
test unless there is also a strong additional family history
suggestive of BRCA1/2. This is because these women will
Table 1 HER2 and ER status in primary BRCA screens




HER2? MS\ 14 0 1 81 82 1.2 0.0–3.6
HER2? MS 14–20 1 2 43 46 6.5 0.0–13.7
ER? HER2? 14–20 1 1 37 39 5.1 0.0–12.1
HER2? MS 20? 3 2 28 33 15 2.9–27.4
ER? HER2? MS 20? 0 1 22 23 4.4 0–12.7
Total HER2? 4 5 152 161 5.6 2.0–9.2
ER- HER2-\50 years 103 25 213 341 37.5 32.4–42.7
ER- HER2- 50? 14 9 61 84 27.3 17.8–36.9
ER- HER2- sporadic\ 50 years 6 2 86 94 8.5 2.9–14.2
ER- HER2- MS\ 14 6 0 79 85 7.0 1.6–12.5
ER- HER2- MS 14–20 15 10 100 125 20.0 13.0–27.0
ER- HER2- MS 20? 96 24 95 215 55.8 49.2–62.4
ER- HER2- MS 30? 51 8 12 71 83.1 74.4–91.8
Total ER- HER2-a 117 34 274 425 35.5 30.9–40.0
a This excludes 23 women with ER- PR? HER2- breast cancers. None had BRCA1/2 mutations
MS manchester score
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still have an increased risk of breast cancer, due to the
likely presence of other breast cancer genes within their
families.
Whilst the low level of detection of BRCA1 and BRCA2
mutations amongst individuals with HER2? breast cancers
is clearly important in assessing carrier likelihood, the
presence of a triple negative breast cancer clearly increases
the likelihood of identifying aBRCA1/2mutation. It has been
suggested that all women with triple negative breast cancer
aged\50 years should be tested for BRCA1/2 mutations
based on the overall detection rate being above 10% [15, 16].
However, this does not take into account the fact that the 10%
threshold is not clearly reached in women with an isolated
breast cancer and no family history [15], In a large study of
1824 cases [15], only 18/209 (8.6%) women with sporadic
triple negative breast cancer diagnosed aged 40–49 years
had an identifiable mutation in BRCA1/2. This is supported
by a detection rate of only 8/94 (8.5%) in sporadic triple
negative cases\50 years in the present study although the
95% confidence intervals do overlap with 10–8.5% (95% CI
2.9–14.2%). Nonetheless, sporadic cases under 40 years do
meet the 10% threshold [17] with 23/149 (18%) of
35–39 year old sporadic cases having a mutation and 23%
(18/91) of those\35 years of age at diagnosis. Clearly 8.6%
is still close to the 10% threshold (the upper 95% CI is
12.4%) and many centres may consider it simpler just to test
all cases\50 years. Additionally, testing women with few
unaffected female relatives and in particular, adopted
women seems appropriate as the 10% threshold may be
reached in these groups.
At the other end of the spectrum, unaffected women
whose mother or sister with high grade triple negative
breast cancer is unavailable for testing and whose family
history is strongly predictive of a BRCA1/2 mutation, (such
as a BOADICEA likelihood in the relative of[80% or a
pathology adjusted Manchester score of 30 or higher)
should be reassured by a negative test. The majority of
their inherited risk would be due to a discoverable BRCA1/
2 mutation and the negative test will greatly reduce their
risk of breast and ovarian cancer, due to the high sensitivity
of current BRCA testing [18].
An example pedigree (Fig. 1) is given to show the
effects of using or not using HER2 status in assessing
breast cancer risk for a 25-year old unaffected woman, with
an affected mother and maternal aunt with breast cancers at
age 35 years. Using the Manchester score [10], a grade 3
triple negative breast cancer would add 4 points to the
Manchester score of 16 to reach 20 points. A HER2?
breast cancer in the mother would reduce the score to 12
points. An unadjusted Manchester score would be equiva-
lent to a 10% probability of BRCA1/2 in the mother. This
would rise to 20% with Triple negative and reduce to 5% if
mother had a HER2? tumour. The likelihoods are halved
in the proband. The attributable risks of breast cancer using
80% penetrance would be only 2% if mother was HER2?
rising to 8% if mother was triple negative (Table 2).
Readouts for Tyrer-Cuzick (changes to BRCA1/2 proba-
bility inferred) and BOADICEA [12] and BRCAPRO [5]
(both with inbuilt pathology adjustments) are shown in
Table 2. Apart from with Tyrer-Cuzick, which does not
have an inbuilt adjustment for pathology, the reduction in
breast cancer risk is only about 2% for testing negative in
the proband when the mother was HER2?. This changes to
a 5.7–10.5% reduction if the mother had triple negative
breast cancer. With BOADICEA the BRCA1/2 probability
in the proband falls from 6.5 to 3.6% with HER2? breast
cancer in mother and rises to 12.3% with triple negative. A
negative BRCA1/2 mutation test only drops absolute breast
cancer risk by 1.7% if mother was Her2? but by nearly 6%
when triple negative. These may underestimate the reduc-
tions due to the default BRCA sensitivities being only 70
and 80% for BRCA1/2 respectively, which is below the
sensitivity of at least 84% (Table 1) for triple negatives
with Manchester scores above 30 in this report and our
previous identification of BRCA1/2 mutations in 81/94
(86%) of breast/ovarian families with Manchester scores of
40? [19]. Whilst the downward adjustment for ER-
HER2? breast cancers in BOADICEA appears appropri-
ate, the programme currently does not adjust for HER2?
breast cancers when they are also ER?. The downward
adjustment for an ER? HER2? breast cancer is only from
6.5 to 4.7% whereas the current report only identified
mutations in 4.5% of ER? HER2? breast cancers when
the average detection rate in ER? HER2- breast cancer
was 14.8% (Table 1). The current data would therefore
suggest that further downward adjustment for HER2
amplification is still necessary for ER? tumours with
BOADICEA. Using BRCAPRO (from Cagene v.6) there is
a greater adjustment with a 10% likelihood in the proband
for BRCA1/2 dropping to 3.4% with HER2? in mother
and rising to 22.5% with triple negative. However, the
breast cancer risk readouts for BRCAPRO only include
familial risk from BRCA1/2 and therefore the reassurance
of reducing risks to population levels after negative
BRCA1/2 testing is inappropriate, [20] as is demonstrated
by the far lower breast cancer risk predictions with
BRCAPRO compared to Tyrer-Cuzick and BOADICEA.
BRCAPRO significantly underestimates breast cancer risk
in the familial breast cancer risk setting [20]. Nonetheless
BRCAPRO does have a specific readout for ER? HER2?
breast cancer that is different to ER- HER2? of 4.8%.
Overall an approximate halving of BRCA probability with
a HER2? breast cancer and doubling with a triple negative
breast cancer appears to fit the current data.
The present study does have some limitations. The
numbers are relatively small compared to large consortia
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[14], but this allows consistency of the approach to clas-
sifying HER2 status. In recent times testing of HER2?
samples will have been relatively reduced because of
implementing a pathology adjusted Manchester score [10].
This will have boosted numbers with triple negative can-
cers at the expense of HER2? cancers thus reducing the
overall rate with HER2? cancers to 13.5% which is below
the overall rate in all breast cancers. It is not clear whether
HER2? breast cancers are more or less likely to have a
familial component outside of BRCA1 and BRCA2,
although TP53 related breast cancers, which make up a
very small proportion of familial breast cancer, are usually
HER2? [21, 22]. Indeed one aspect of the present study is
that sporadic HER2? breast cancer is extremely unlikely to
have a BRCA1/2 mutation but\35 years may well have a
TP53 mutation. With more women with breast cancers at
early ages undergoing mutation testing to determine
treatment even without a family history, extra weight
should be given to discussing TP53 in very young sporadic
HER2? breast cancers than the very small possibility of
BRCA1/2. Although PR was not collected systematically it
was when both ER and HER2 were negative. In a large
study of 631 breast cancers that were HER2- and ER-
only 43 (6.8%) were PR positive [23] similar to the 23/438
(5.2%) in the current study.
In conclusion the present study demonstrates the great
importance of properly assessing breast cancer HER2 sta-
tus when determining the likelihood of a BRCA1/2 muta-
tion. Where possible this information should be sought,
especially when testing unaffected women whose affected
relative with breast cancer is unavailable for genetic test-
ing. Use of well validated programmes that take into
Woman's age is 25 years.
Age at menarche is unknown.
No information about childbirth.
Menopause status is unknown.
Height is unknown.
Weight is unknown.
Woman has never used HRT.
Risk after 10 years is 2.225%.
10 year population risk is 0.226%.
Lifetime risk is 29.16%.
Lifetime population risk is 10.26%.
Probability of a BRCA1 gene is 7.126%.














Fig. 1 Tyrer-Cuzick risk
readout of unadjusted breast
cancer risk estimation of case
example
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account the possibility of familial risk other than BRCA1/2
should be used although further adjustments may need to
be made before these models fully account for the effects
of HER2? status.
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